homovanillic acid has been researched along with Disease Exacerbation in 21 studies
Homovanillic Acid: A 3-O-methyl ETHER of (3,4-dihydroxyphenyl)acetic acid.
homovanillate : A hydroxy monocarboxylic acid anion which is obtained by deprotonation of the carboxy group of homovanillic acid.
homovanillic acid : A monocarboxylic acid that is the 3-O-methyl ether of (3,4-dihydroxyphenyl)acetic acid. It is a catecholamine metabolite.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The value of the tumour markers vanillylmandelic acid (VMA) and homovanillic acid (HVA) in urine (u) and serum (s), neurone-specific enolase (NSE), and lactate dehydrogenase (LDH) in the early prediction of relapse/progression in neuroblastoma is not known." | 3.72 | Tumour markers are poor predictors for relapse or progression in neuroblastoma. ( Berthold, F; Hero, B; Hunneman, DH; Simon, T, 2003) |
| "Current research on Parkinson's disease (PD) pathogenesis requires relevant animal models that mimic the gradual and progressive development of neuronal dysfunction and degeneration that characterizes the disease." | 1.42 | Progressive nigrostriatal terminal dysfunction and degeneration in the engrailed1 heterozygous mouse model of Parkinson's disease. ( Beauvais, G; Brundin, P; Escobar Galvis, ML; Feinstein, TN; Fuchs, J; Ghosh, A; Joshi, RL; Lipton, JW; Lundblad, M; Medicetty, S; Nordströma, U; Prochiantz, A; Pulikkaparambil Sasidharan, BC; Roholt, A; Steiner, JA, 2015) |
| "Our data show that disease progression produces an early large decay of DA levels, followed by a stabilization." | 1.35 | Correlation between changes in CSF dopamine turnover and development of dyskinesia in Parkinson's disease. ( Brusa, L; Fedele, E; Fornai, F; Galati, S; Hainsworth, AH; Lunardi, G; Moschella, V; Pierantozzi, M; Pisani, A; Rossi, S; Stanzione, P; Stefani, A; Tropepi, D, 2009) |
| "Homovanillic acid levels were significantly lower only in the PRMS group, with a negative correlation to duration of illness, and a strong negative correlation to EDSS score, but not to MSSS." | 1.35 | Relationship of CSF neurotransmitter metabolite levels to disease severity and disability in multiple sclerosis. ( Evangelopoulos, ME; Karahalios, G; Koutsis, G; Mandellos, D; Markianos, M; Sfagos, C, 2009) |
| "Ten patients with advanced Parkinson's disease (Hoehn & Yahr stage IV) were medicated with tolcapone." | 1.31 | COMT-inhibition increases serum levels of dihydroxyphenylacetic acid (DOPAC) in patients with advanced Parkinson's disease. ( Buhmann, C; Oechsner, M; Strauss, J; Stuerenburg, HJ, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (14.29) | 18.2507 |
| 2000's | 13 (61.90) | 29.6817 |
| 2010's | 5 (23.81) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nordströma, U | 1 |
| Beauvais, G | 1 |
| Ghosh, A | 1 |
| Pulikkaparambil Sasidharan, BC | 1 |
| Lundblad, M | 1 |
| Fuchs, J | 1 |
| Joshi, RL | 1 |
| Lipton, JW | 1 |
| Roholt, A | 1 |
| Medicetty, S | 1 |
| Feinstein, TN | 1 |
| Steiner, JA | 1 |
| Escobar Galvis, ML | 1 |
| Prochiantz, A | 1 |
| Brundin, P | 1 |
| Stefani, A | 2 |
| Pierantozzi, M | 2 |
| Olivola, E | 1 |
| Galati, S | 2 |
| Cerroni, R | 1 |
| D'Angelo, V | 1 |
| Hainsworth, AH | 2 |
| Saviozzi, V | 1 |
| Fedele, E | 2 |
| Liguori, C | 1 |
| Lunardi, G | 1 |
| Tropepi, D | 1 |
| Moschella, V | 1 |
| Brusa, L | 1 |
| Rossi, S | 1 |
| Fornai, F | 1 |
| Stanzione, P | 1 |
| Pisani, A | 1 |
| Markianos, M | 1 |
| Koutsis, G | 1 |
| Evangelopoulos, ME | 1 |
| Mandellos, D | 1 |
| Karahalios, G | 1 |
| Sfagos, C | 1 |
| Zádori, D | 1 |
| Geisz, A | 1 |
| Vámos, E | 1 |
| Vécsei, L | 1 |
| Klivényi, P | 1 |
| Tanaka, M | 1 |
| Kigasawa, H | 1 |
| Kato, K | 1 |
| Ijiri, R | 1 |
| Nishihira, H | 1 |
| Aida, N | 1 |
| Ohama, Y | 1 |
| Tanaka, Y | 1 |
| Willemsen, MA | 1 |
| Verbeek, MM | 1 |
| Kamsteeg, EJ | 1 |
| de Rijk-van Andel, JF | 1 |
| Aeby, A | 1 |
| Blau, N | 1 |
| Burlina, A | 1 |
| Donati, MA | 1 |
| Geurtz, B | 1 |
| Grattan-Smith, PJ | 1 |
| Haeussler, M | 1 |
| Hoffmann, GF | 1 |
| Jung, H | 1 |
| de Klerk, JB | 1 |
| van der Knaap, MS | 1 |
| Kok, F | 1 |
| Leuzzi, V | 1 |
| de Lonlay, P | 1 |
| Megarbane, A | 1 |
| Monaghan, H | 1 |
| Renier, WO | 1 |
| Rondot, P | 1 |
| Ryan, MM | 1 |
| Seeger, J | 1 |
| Smeitink, JA | 1 |
| Steenbergen-Spanjers, GC | 1 |
| Wassmer, E | 1 |
| Weschke, B | 1 |
| Wijburg, FA | 1 |
| Wilcken, B | 1 |
| Zafeiriou, DI | 1 |
| Wevers, RA | 1 |
| Meng, T | 1 |
| Zheng, ZH | 1 |
| Liu, TT | 1 |
| Lin, L | 1 |
| Tillerson, JL | 1 |
| Cohen, AD | 1 |
| Caudle, WM | 1 |
| Zigmond, MJ | 1 |
| Schallert, T | 1 |
| Miller, GW | 1 |
| Simon, T | 1 |
| Hero, B | 1 |
| Hunneman, DH | 1 |
| Berthold, F | 1 |
| Pons, R | 1 |
| Ford, B | 1 |
| Chiriboga, CA | 1 |
| Clayton, PT | 1 |
| Hinton, V | 1 |
| Hyland, K | 1 |
| Sharma, R | 1 |
| De Vivo, DC | 1 |
| Scheller, C | 1 |
| Sopper, S | 1 |
| Jenuwein, M | 1 |
| Neuen-Jacob, E | 1 |
| Tatschner, T | 1 |
| Grünblatt, E | 1 |
| ter Meulen, V | 1 |
| Riederer, P | 1 |
| Koutsilieri, E | 1 |
| Abdenur, JE | 1 |
| Abeling, N | 1 |
| Specola, N | 1 |
| Jorge, L | 1 |
| Schenone, AB | 1 |
| van Cruchten, AC | 1 |
| Chamoles, NA | 1 |
| Espino, A | 1 |
| Calopa, M | 1 |
| Ambrosio, S | 1 |
| Ortolà, J | 1 |
| Peres, J | 1 |
| Navarro, MA | 1 |
| Teicher, MH | 1 |
| Andersen, SL | 1 |
| Campbell, A | 1 |
| Gelbard, HA | 1 |
| Baldessarini, RJ | 1 |
| Brashear, A | 1 |
| Butler, IJ | 1 |
| Ozelius, LJ | 1 |
| Kramer, PI | 1 |
| Farlow, MR | 1 |
| Breakefield, XO | 1 |
| Dobyns, WB | 1 |
| Elsworth, JD | 1 |
| Taylor, JR | 1 |
| Sladek, JR | 1 |
| Collier, TJ | 1 |
| Redmond, DE | 1 |
| Roth, RH | 1 |
| Yoneda, A | 1 |
| Oue, T | 1 |
| Imura, K | 1 |
| Inoue, M | 1 |
| Yagi, K | 1 |
| Kawa, K | 1 |
| Nishikawa, M | 1 |
| Morimoto, S | 1 |
| Nakayama, M | 1 |
| Bezard, E | 1 |
| Dovero, S | 1 |
| Prunier, C | 1 |
| Ravenscroft, P | 1 |
| Chalon, S | 1 |
| Guilloteau, D | 1 |
| Crossman, AR | 1 |
| Bioulac, B | 1 |
| Brotchie, JM | 1 |
| Gross, CE | 1 |
| Barthwal, MK | 1 |
| Srivastava, N | 1 |
| Dikshit, M | 1 |
| Oechsner, M | 1 |
| Buhmann, C | 1 |
| Strauss, J | 1 |
| Stuerenburg, HJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| An Examination of Potential Neurochemical and Cognitive Mediators of the Relationship Between Mindfulness and Emotion Regulation in Individuals With Multiple Sclerosis: An Internet Based Self-Guided Pilot Study.[NCT02391298] | 26 participants (Actual) | Interventional | 2014-12-31 | Completed | |||
| PHASE III MULTICENTRE TRIAL OF TREATMENT OF NEUROBLASTOMA IN CHILDREN AND ADOLESCENTS[NCT00002802] | Phase 3 | 500 participants (Anticipated) | Interventional | 1990-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for homovanillic acid and Disease Exacerbation
| Article | Year |
|---|---|
Aromatic L-amino acid decarboxylase deficiency: clinical features, treatment, and prognosis.
Topics: Adolescent; Amino Acid Metabolism, Inborn Errors; Aromatic-L-Amino-Acid Decarboxylases; Child; Child | 2004 |
1 trial available for homovanillic acid and Disease Exacerbation
| Article | Year |
|---|---|
CSF somatostatin increase in patients with early parkinsonian syndrome.
Topics: Aged; Disease Progression; Female; Homovanillic Acid; Humans; Male; Middle Aged; Parkinson Disease, | 1995 |
19 other studies available for homovanillic acid and Disease Exacerbation
| Article | Year |
|---|---|
Progressive nigrostriatal terminal dysfunction and degeneration in the engrailed1 heterozygous mouse model of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Autophagy; Corpus Striatum; Disease Models, Animal; Disease | 2015 |
Homovanillic acid in CSF of mild stage Parkinson's disease patients correlates with motor impairment.
Topics: Aged; Antiparkinson Agents; Biomarkers; Disease Progression; Female; Homovanillic Acid; Humans; Levo | 2017 |
Correlation between changes in CSF dopamine turnover and development of dyskinesia in Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Age of Onset; Aged; Disease Progression; Dopamine; Dyskinesias; Homo | 2009 |
Relationship of CSF neurotransmitter metabolite levels to disease severity and disability in multiple sclerosis.
Topics: Adolescent; Adult; Disability Evaluation; Disease Progression; Female; Homovanillic Acid; Humans; Hy | 2009 |
Valproate ameliorates the survival and the motor performance in a transgenic mouse model of Huntington's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Animal; Corpus Striatum; Disease Models, Animal; | 2009 |
A prospective study of a long-term follow-up of an observation program for neuroblastoma detected by mass screening.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Combined Modality Therapy; Disease Progression; Female; Fo | 2010 |
Tyrosine hydroxylase deficiency: a treatable disorder of brain catecholamine biosynthesis.
Topics: Age of Onset; Amino Acid Metabolism, Inborn Errors; Brain; Brain Diseases; Catecholamines; Child, Pr | 2010 |
Contralateral retinal dopamine decrease and melatonin increase in progression of hemiparkinsonium rat.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Chromatography, High Pressure Liquid; Disease Progression; | 2012 |
Forced nonuse in unilateral parkinsonian rats exacerbates injury.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Apomorphine; Behavior, Animal; Brain Chemistry; Casts, Surg | 2002 |
Tumour markers are poor predictors for relapse or progression in neuroblastoma.
Topics: Adolescent; Biomarkers, Tumor; Bone Marrow Neoplasms; Child; Child, Preschool; Clinical Trials as To | 2003 |
Early impairment in dopaminergic neurotransmission in brains of SIV-infected rhesus monkeys due to microglia activation.
Topics: Animals; Blotting, Western; Brain; Cell Separation; Chromatography, High Pressure Liquid; Cyclic AMP | 2005 |
Aromatic l-aminoacid decarboxylase deficiency: unusual neonatal presentation and additional findings in organic acid analysis.
Topics: Aromatic-L-Amino-Acid Decarboxylases; Biogenic Amines; Biomarkers; Disease Progression; Female; Foll | 2006 |
Progressive accumbens degeneration after neonatal striatal 6-hydroxydopamine in rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Animals, Newborn; Caudate Nucleus; Chromatography, High Pre | 1998 |
Rapid-onset dystonia-parkinsonism: a report of clinical, biochemical, and genetic studies in two families.
Topics: Adolescent; Adult; Age of Onset; Diagnosis, Differential; Disease Progression; Dystonia; Family Heal | 1998 |
Striatal dopaminergic correlates of stable parkinsonism and degree of recovery in old-world primates one year after MPTP treatment.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Chlorocebus aethiops; Disea | 2000 |
Observation of untreated patients with neuroblastoma detected by mass screening: a "wait and see" pilot study.
Topics: Adrenal Gland Neoplasms; Biomarkers, Tumor; Chemotherapy, Adjuvant; Disease Progression; Follow-Up S | 2001 |
Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Autoradiograp | 2001 |
Role of nitric oxide in a progressive neurodegeneration model of Parkinson's disease in the rat.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; Animals; Corpus Striatum; Disease Models, Animal; | 2001 |
COMT-inhibition increases serum levels of dihydroxyphenylacetic acid (DOPAC) in patients with advanced Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Aged, 80 and over; Antiparkinson Agents; Benzophenones; Catech | 2002 |